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Abstract
Purpose of Review This review focuses on new pathogenesis and clinical-therapeutic aspects of obstetric anti-phospholipid
syndrome (ob-APS) in the last 5 years.
Recent Findings The pathogenesis of ob-APS is multifactorial, including placental infarctions, infiltration of inflammatory cells
that cause acute and chronic inflammation, leading to uncontrolled inflammation and poor pregnancy outcomes. A preconception
counseling and a patient-tailored treatment are fundamental to improve maternal and fetal outcomes. Thanks to conventional
treatment, based on low-dose aspirin and heparin, 70% of women with ob-APS can have successful pregnancies. Women with
positive anti-phospholipid antibodies (aPL) without clinical manifestations (“aPL carriers”) or with obstetric manifestation not
fulfilling ob-APS criteria need to be further investigated in order to assess their best management.
Summary Great interest has been given to drugs that could interact in the pathophysiological mechanisms, such as
hydroxychloroquine, statins, and eculizumab. These drugs could be considered for patients refractory to conventional therapy.
Keywords Anti-phospholipid syndrome . Anti-phospholipid antibodies . Pregnancy morbidity . Obstetric complications .
Pathogenesis . Management . Treatment
Introduction
Anti-phospholipid syndrome (APS) is a systemic autoimmune
disease characterized by arterial and/or venous thrombosis
and/or obstetric morbidity mediated by anti-phospholipid an-
tibodies (aPL). These pathogenic autoantibodies are deter-
mined by means of lupus anticoagulant (LA), IgM and IgG
anti-cardiolipin (aCL), and anti-β2glycoprotein-I (aβ2GPI)
antibodies; their presence should be confirmed in two differ-
ent occasions at least 12 weeks apart [1].
Even though the syndrome was initially described as a
single disorder, the distinction between obstetric (ob-
APS) and thrombotic APS has been well established dur-
ing the last 10 years given the following observations:
(1) patients can display vascular thrombosis with no
pregnancy complications or, alternatively, obstetric man-
ifestations alone [2]; (2) the coexistence of both throm-
bosis and miscarriages only affects about 2.5–5% of APS
pregnancies [3]; (3) IgG fractions from pure ob-APS dis-
play different effects in vitro on monocyte and tropho-
blast cells [4].
The ob-APS can affect both the mother and the fetus [5]. The
clinical criteria of ob-APS were revised in 2006, as follows:
history of three early consecutive miscarriages (< 10 weeks of
gestation, withmaternal anatomic or hormonal abnormalities and
paternal and maternal chromosomal causes excluded), and/or
one stillbirth (> 10 weeks of gestation, with normal fetal mor-
phology documented by ultrasound or by direct examination of
the fetus), and/or one intra-uterine growth restriction (IUGR) or a
premature birth before 34 weeks of gestation due to pre-
eclampsia (PE) or eclampsia or placental insufficiency (abnormal
or non-reassuring fetal surveillance test, abnormal Doppler flow
velocimetry waveform analysis suggestive of fetal hypoxemia,
oligohydramnios, and postnatal birth weight less than the 10th
percentile for the gestational age) [1]. Furthermore, pregnant
women with ob-APS have an increased risk of thrombosis [5],
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thrombocytopenia, and HELLP syndrome (hemolytic anemia,
elevated liver enzymes, and low platelet count) [6].
This narrative review summarizes the latest research on
pathological, clinical, and therapeutically aspects of ob-APS.
Epidemiology
APS can occur as an isolated disease (primary) or associatedwith
other systemic autoimmune diseases (secondary), mainly with
systemic lupus erythematosus (SLE). Robust epidemiological
data from large controlled population studies are still lacking.
Women are more commonly affected by APS than men, in pri-
mary (3.5:1 ratio) as well as in secondary APS (7:1) [7].
According to the review of the literature, aPL are positive in
approximately 6% of women with pregnancy morbidities (preg-
nancy losses, IUGR, PE/eclampsia, and HELLP syndrome) [8].
Pathogenesis
The exact mechanisms involved in the prothrombotic state of
the disease (causing thrombosis and/or obstetr ic
complications) remain yet to be fully explained. aPL have
the ability to induce thrombus formation in the arterial and/
or venous vasculature and/or microcirculation by targeting
and affecting the functionality of a variety of cell types such
as endothelial cells, monocytes, leukocytes, neutrophils, and
platelets on the vascular aspect of the disease, and trophoblasts
and decidual cells during gestation; the irregular function of
these cells contributes in the disease development [9]. Several
studies have reported that aPLs have the capacity to interact
with the trophoblast and the endothelial cell monolayer, by
disrupting the anticoagulant annexin A5 shield, resulting in
fetal loss [10].
However, DeWolf et al. and Stone et al., in histopathologic
findings in the human placenta samples, have demonstrated
that other non-thrombotic mechanisms, such as inflammation,
may be involved in the pathogenesis of ob-APS, besides pla-
cental infarctions [11, 12] (Table 1). Viall et al., in a recent
meta-analysis of the histopathologic findings in the placentae
from aPL-affected pregnancies, revealed five features associ-
ated with aPL: (1) placental infarction, (2) impaired spiral
artery remodeling, (3) decidual inflammation, (4) increased
syncytial knots, and (5) decreased vasculosyncytial mem-
branes [36].
Table 1 Pathogenic mechanisms of ob-APS
Pathogenic mechanism References
Thrombosis In vitro models:
• aPL interact with endothelial cells, predominately by binding toβ2GPI expressed on the cell membranes of different cell types,
and induces a procoagulant and pro-inflammatory endothelial state
[13]
• aPL upregulate TF expression on endothelial cells and blood monocytes, as well as, by promoting endothelial leukocyte
adhesion, cytokine secretion and PGE2 synthesis
[14–17]
• aPL recognize phospholipid-binding proteins expressed on platelets and induces platelet aggregation induced by another
agonist
[18, 19]
• aPL interferes with plasma components of the coagulation cascade by inhibiting anticoagulant activity, reducing fibrinolysis,




• infusion of aPL with or without β2GPI alters expression of endothelial adhesion molecules, causing upregulation of NO and
TF expression causes vascular abnormalities (especially in the arterial endothelium)
• Thrombotic effects were produced using affinity-purified anti-β2GPI IgG, and were inhibited by specific absorption of
anti-β2GPI activity
[22, 23]
Inflammation In vitro models:
• aPL, via TLR-4 and MyD88, induce trophoblasts to secrete IL-1β and IL-8
[24]
• Downstream of MyD88, IL-1β secretion is mediated by uric acid, which in turn activates NLRP3 inflammasome to process
IL-1β
[25]
• Trophoblast inflammation is driven by aPL induced miR-146a-3p and uric acid which activate TLR-8 and the NLRP3
inflammasome in trophoblasts
[26]
• Decidual stromal cells treated with a β2GPI-dependent aPL monoclonal antibody, express an upregulation of genes involved
in the inflammatory response
[27, 28]
In vivo models:
• aPL located in the placenta and inflammation (by complement activation and recruitment and stimulation of neutrophils is the
main factor in placental insufficiency, fetal loss, and IUGR)
[29–31]




•Animals deficient in complement components or complement receptors, or treated with complement inhibitors were protected
from thrombogenic effect of aPL
[22, 32–34]
• Complement deposition was found in placenta tissue from women positive for aPL, in retrospective study [35]
aPL anti-phospholipid antibodies, LAA low avidity autoantibodies, β2GPI β2 glicoprotein I, NO nitric oxide, TF tissue factor, IL interleukin, TLR toll-
like receptor, MyD88 myeloid differentiation factor 88, miR microRNA
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aPL recognizing β2GPI have been shown to be pathogenic
in ob-APS due to its constant expression on the cell surface
[10]. The placenta is a major target for β2GPI-dependent
pathogenic aPL binding and consequently reducing tropho-
blast differentiation/invasiveness [10]. This was demonstrated
by 14 studies that investigated trophoblast invasion in the
presence of aPL in vitro. Both the outer placental
syncytiotrophoblast (STB) and the extravillous trophoblast
(EVT) bind to aβ2GPI antibodies differently; the STB inter-
nalized aPL via a low-density lipoprotein receptor (LDLR),
and the EVT maintains aPL on the cell surface [37••, 38].
During the first trimester, if maternal spiral arteries are not
sufficiently plugged by endovascular trophoblasts, then strong
stream of blood from the arteries may physically or oxidatively
damage the placenta and contribute to early pregnancy loss
[39]. As gestation progresses, if trophoblasts do not transform
the maternal spiral arteries into wide-bore tubes adapted for
efficient blood flow, the placenta may become hypoperfused
and undergo ischemia-reperfusion injury, leading to PE and
IUGR [40].
In vitro studies, using human first-trimester EVT, demon-
strated that aPL recognizing β2GPI trigger EVT to produce
elevated levels of pro-inflammatory cytokines and
chemokines, inhibit spontaneous trophoblast migration, in-
crease trophoblast antiangiogenic soluble endoglin secretion,
and disrupt trophoblast-endothelial interactions in a model of
spiral artery transformation, reproducing similar changes to
those in PE [41, 42].
Two in vitro studies demonstrated that aPL induce tropho-
blasts inflammation by secreting interleukin-1β (IL-1β) and
IL-8 via activation of Toll-like receptor 4 (TLR-4) and its
adapter protein myeloid differentiation factor 88 (My88) [24,
25]. Downstream of My88 and IL-1β is mediated by uric acid
which activates NLRP3 inflammasome to process IL-1β and
IL-8 production; downstream of TLR-4 is mediated by induc-
tion of microRNA-146a-3p (miR 146a-3p). aPL-induced
miR-146a-3p and uric acid act as endogenous secondary sig-
nals for activation of TLR-8 and NLRP3 inflammasome in
trophoblasts, to drive trophoblast inflammation [43]. A recent
in vitro study demonstrated that aβ2GPI aPL induce altered
TAM receptor signaling (negative regulator of TLR) and au-
tophagy causing, respectively, subsequent TLR4-mediated
IL-8 response and NLRP3 inflammasome-mediated IL-1 ac-
tivity leading to a robust inflammatory response [44•].
Reduced trophoblast migration and invasion caused by
aPL are mediated by apolipoprotein E receptor 2 (ApoER2)
which interacts with dimerized β2GPI. ApoER2 serves as a
target for anti-β2GPI-β2GPI complexes leading to reduced
pro-migratory IL-6 and STAT-3 activity. In vivo studies have
demonstrated the role of ApoER2 in aPL-mediated feta loss
and IUGR [27].
However, there seems to be a difference between the path-
ogenesis of aPL-related recurrent pre-embryonic loss and late
pregnancy morbidity. Especially for early pregnancy losses,
the effects of aPL on placentation may be relevant, as these
autoantibodies increase apoptosis and reduce invasion of the
trophoblast [45]. The complement system, instead, seems to
play a crucial role in causing pregnancy loss and fetal growth
restriction. Shamonki et al, in human studies, showed that
placenta of women with aPL has increased complement
deposition of C4d and C3b, supporting the hypothesis that
complement activation is involved in the pathogenesis of
aPL-related pregnancy complications [35, 36]. Inherited
hypofunctional variants of complement regulators provide
an increased risk of PE in women with SLE and/or aPL
[46]. A recent study in pregnant patients with SLE and/or
aPL, increased levels of Bb and sC5b-9, complement
activation products, early in pregnancy were significantly
associated with adverse pregnancy outcomes (APOs)
[47•].
A mediator that plays an important role in the complement
activation is the tumor necrosis factor (TNF). This mediator
links complement C5a-C5aR interactions and pathogenic aPL
to fetal damage [48]. aPL that target decidual tissue cause a
rapid increase in decidual and systemic TNF levels. Studies on
mice have suggested that miscarriages induced by aPL are less
frequent in those who are deficient in TNF or treated with
TNF blockade. In humans, TNF contributes to the pathogen-
esis of poor pregnancy outcomes: TNF-α increases through-
out pregnancy and has been related to miscarriages, fetal
losses, PE, and preterm birth as well as IL-10 reduction [49].
As described above, placental infarction due to thrombus
occluding spiral artery is a common histopathologic finding in
ob-APS. In two studies that examined the placentae from first
trimester abortions, placental thrombotic infarction or spiral
artery thrombosis were not detected, this suggests that this
phenomenon could be associated with late pregnancy compli-
cations [50, 51].
Another factor that also plays an important role in the path-
ogenesis of PE in SLE patients is Interferon (IFN)α. In vitro
and in vivo studies suggest that elevated IFN-α levels contrib-
ute in developing PE by sensitizing maternal endothelium to
the antiangiogenic effects of soluble Flt-1 and by inhibiting
transcription of proangiogenic VEGF, necessary for homeo-
stasis in some vascular beds. Increased IFN-α levels may
identify SLE patients who have an increased risk of develop-
ing placenta-mediated pregnancy complications; this may be
related to the vasculopathic effects of elevated IFNα in active
SLE patients who experience PE early in pregnancy [52].
Predictive Factors of Obstetrical Outcome
Risk factors associated with adverse pregnancy outcomes in-
clude: high number of previous pregnancy losses [53], throm-
botic APS [54, 55], associated autoimmune diseases (SLE)
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[56], hypocomplementemia at conception [57, 58, 59•], high
antibody titer [60, 61], and the number and the type (LAC and
IgG aCL) of different autoantibodies detected, with an in-
creased risk in patients with a triple-positive profile [55, 61,
62]. The presence of triple aPL positivity seems to be due to
antibodies directed to the first domain of β2GPI, anti-D1 [63,
64]. These pathogenic antibodies are more frequent in patients
having higher antibody titers and triple positivity for aPL. This
seems to make sense because these pathogenic antibodies
have LA activity [65]. On the other hand, single positivity
for the aPL profile seems to be associated with positive tests
for anti-domain 4/5, considering these are non-pathogenic an-
tibodies [66]. Interestingly, it has been recently demonstrated
that anti-D1 are significantly associated with pregnancy mor-
bidity, in particular late pregnancy morbidity (late pregnancy
losses and premature delivery) [67•]. Data from the study
PROMISSE showed that LAwas the only aPL associated with
APOs after the first trimester [68].
As for the antibody titer, conflicting results exist. Even
though high positive antibody titers are associated with ad-
verse pregnancy outcome [60, 61], there is increasing evi-
dence that patients with low-titer aPL can experience poor
pregnancy outcomes similarly to high-titer aPL patients
[69–73]. These observations suggest that in contrast to throm-
botic events, low-titer aPL can play a significant role in ob-
APS and that the current classification criteria may not allow
to include all the ob-APS cases.
Future prospective studies with homogeneous study popu-
lation and design are needed to clarify these findings and to
identify additional risk factors and better delineate the optimal
personalized risk-based management of these women.
Clinical Manifestations
The frequency of obstetric complications varies among stud-
ies and depends on the selected APS phenotype and on the
treatment regimen [74]. The rates of PE range from 2 to 17%,
venous thrombosis 2–3%, IUGR 3–12%, preterm delivery
11–19%, hypotrophy 11–23%, and neonatal complications
11–13% [75, 76]. In the PROMISSE study, Lockshin et al.
reported an overall APO of 19% after exclusion of early preg-
nancy loss [76].
In a multicenter prospective study, the Euro-Phospholipid
project, 1000 APS European patients were followed during a
10-year period [77••]. A total of 188 pregnancies occurred in
127 women and 72.9% (n = 137) of pregnancies succeeded in
having one or more live births. The most common obstetric
complication was early pregnancy loss (< 10 weeks) in 16.5%
(n = 31) of pregnancies. The obstetric morbidity rate was low-
er during the last 5 years of the study; no women developed
PE/eclampsia. Regarding fetal morbidity, the most frequent
manifestations were birth prematurity (48.2% of the total live
birth) and IUGR (26.3%) [77••]. In a European cohort of 247
ob-APS (EUROAPS), live births were achieved in 192/247
cases (77.7%). Of these 192 successful cases, 174 (89.7%)
received treatment and 18 (10.3%) did not. Obstetric compli-
cations appeared in 129/247 (52.2%) cases, although not all
ended in fetal demise or stillbirth. Fetal loss was the most
frequent fatal complication (17.80%) followed by miscarriage
(16.27%), with stillbirth being relatively infrequent (4.69%).
Prematurity was the most common non-fatal complication
(47.28%). Early and severe PE together with HELLP syn-
drome appeared in more than 18% of these women. IUGR
complicated 15.50% of cases [78]. Patients with ob-APS
mainly suffer from obstetrical morbidity, but the risk of throm-
botic events persists during the follow-up [5, 78, 79].
Management of ob-APS
General Considerations
The management of women with ob-APS includes a close
surveillance and tailored treatment before, during, and after
pregnancy to optimize maternal and fetal pregnancy
outcomes.
As stated in the EULAR recommendations [80••], a pre-
conception counseling is fundamental to assess any previous
pregnancy complications and/or thrombotic events, the pres-
ence of the “APS non-criteria manifestations” [80••], other
associated autoimmune diseases (SLE), genetic thrombotic
risk factors, major organ involvement, the presence of other
comorbidities, life style risk factors (e.g., smoking, alcohol
consumption), medications that may compromise fetal devel-
opment, and the risk stratification according the aPL profile
(Table 2).
Thanks to counseling and risk stratification assessment, it
is possible to set up preventive strategies and a patient-tailored
monitoring plan. If possible, visits and blood tests should be
performed monthly, although a less tight schedule can be
planned for low-risk patients. In addition to the routine first
and second ultrasonography screening, patients with ob-APS
should undergo supplementary surveillance in the third tri-
mester, at monthly intervals, based on biometric and
Doppler findings, in order to diagnose an early or late IUGR
and plan the time of delivery [80••]. In patients with current or
past renal involvement, blood pressure and 24-h urine protein-
uria should be regularly monitored.
Obstetric APS
Current standard of care for women with ob-APS includes
prophylactic or therapeutic dose of heparin (unfractionated
heparin-UFH- or low-molecular weight heparin-LMWH)
combined with low dose of aspirin (LDA) (75–100 mg/day)
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Table 2 Suggested management of obstetric-APS
Management
General measures Folic acid preferably for at least 3 months prior to conception and throughout pregnancy
Calcium and vitamin D during pregnancy
During puerperium, prevent immobility and use compression stockings if history
of thrombosis
“Criteria” ob-APS Pregnancy Conventional treatment:
LDAa)□ (75–100 mg/day) plus prophylactic LMWH□ or UFH□
Refractory ob-APS
(with previous pregnancy failure on conventional treatment)
LDAa)□ (75–100 mg/day) plus prophylactic/therapeutic LMWH□ or UFH□
and consider one or more of the following additional treatments:
- Prednisolone (10 mg/day) in the first trimester (0–14 weeks of gestation)
- IVIG (400 mg/kg/day for 5 consecutive days or 1 g/kg daily for 2 consecutive days
- Plasmapheresis (3 to 5 consecutive days)
- HCQ (5–6 mg/kg/day)
- Pravastatin (20 mg/day)
Puerperium Prophylactic LMWH□ or UFH□ for 4–6 weeks
APS patients with previous thrombosis Pregnancy Stop VKA□ (before the sixth week of gestation)**
start LDAa)□ (75–100 mg/day) plus therapeutic UFH□ or LMWH□
Puerperium Therapeutic UFH or LMWH
OR
VKA**
CAPS, during pregnancy First-line therapy
UFH*□ (80 U/kg IV bolus) then continuous infusion of 18 U/kg/h
Glucocorticoids methylprednisolone (IV)
500–1000 mg/day for 1 to 3 days
and
slowly reduce to 1–0.5 mg/kg/day
(depending on clinical condition)
Plasmapheresis (three to 5 consecutive days)
and/or
IVIG (2 schemes, after plasmapheresis)




RTX [375 mg/m2 (IV) 1/week during 1 month or 1 g twice 15 days apart]
or
Eculizumab [900 mg (IV)/week for 4 weeks then 1200 mg/2 weeks]
APS associated to autoimmune diseases (e.g., SLE) Pregnancy LDAa)□ (75–100 mg/day) plus prophylactic/therapeutic LMWH□ or UFH□
(prophylactic/therapeutic weight-adjusted dose depending the main clinical
manifestation of APS, thrombotic or obstetric)
and
HCQ (5–6 mg/kg/day)
Puerperium Prophylactic UFH or LMWH for 4–6 weeks
aPL carriers or women not fulfilling clinical criteria for ob-APS Pregnancy
•“Low-risk”# aPL profile LDAa)□ (75–100 mg/day)
•“High-risk”# aPL profile and/or additional risk factors and/or APS
non-criteria manifestations
LDAa)□ (75–100 mg/day) plus UFH□ or LMWH□ (prophylactic weight-adjusted
dose depending on aPL profile plus concomitant risk factors and/or additional
APS non-criteria manifestations)
According to individual risk stratification, consider adding HCQ 5–6 kg/day
Puerperium Prophylactic UFH□ or LMWH□ for 4–6 weeks
aPL anti-phospholipid antibodies, APS anti-phospholipid syndrome, CAPS catastrophic anti-phospholipid syndrome, IV intravenous, IVIG intravenous
immunoglobulins, ob-APS obstetric-anti-phospholipid syndrome, RTX rituximab, UFH unfractionated heparin, U units, LMWH low molecular weight
heparin, kg kilogram, hr hour, mg milligram
# “low-risk” profile (patients with isolated, intermittently positive aCL, or aβ2GPI at low-medium titers); “high-risk” aPL profile: LA positivity, or
“triple positivity”—LA + aCL + aβ2GPI—or medium-high titers of IgG aCL or IgG aβ2GPI
* Acute phase
**Warfarin: teratogenic, especially between the 6th and 10th week of gestation; risk of fetal bleeding specially after the 32th week of gestation. During
puerperium, it can be restarted after bridging therapy with heparin
a) Depending on formulations of the drug available in different countries
LDA should be started prior to conception and stopped before delivery depending on the local protocol. Heparin should be started when pregnancy is
confirmed (at positive pregnancy test or after ultrasound confirmation, depending on local protocols) and stopped before delivery depending on the type
of heparin and the mode of delivery
□ In pregnant women with APS and thrombocytopenia, a frequent APS non-criteria manifestation, the use of heparin, LDA, and VKA should be
carefully evaluated due to the increased risk of bleeding. If thrombocytopenia is mild, above 50 × 109 /L, and no signs of bleeding, anti-thrombotic
treatment can be continued. If platelet count is below 50 × 109 /L, the use of anti-thrombotic drugs should be weighed against the risk of clotting
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[80••, 81]. The LDA should be preferably given prior to con-
ception, and LMWH or UFH treatment should begin as soon
as pregnancy is confirmed. It has been demonstrated that both
UFH plus LDA and LMWH plus LDA are effective in the
management of recurrent abortion secondary to APS [82–84].
Given the similar efficacy with both types of heparin, LMWH
could be preferred for practical reasons due to its route of
administration and no need for monitoring and for its lower
risk of osteoporosis [85]. Regarding the dosage of
prophylactic heparin, it is unknown if fixed doses are equal
or more efficacious than adjusted ones in preventing APOs.
Just one prospective study showed that weight-adjusted, once
daily, doses of LMWH combined with LDA could be an effi-
cacious treatment option for pregnant APS patients with no
history of thrombosis [56]. However, in clinical practice, most
physicians use a fixed dosage of LMWH in pregnant APS.
In ob-APS patients with higher risk to develop a first
thrombotic event, due to the “high-risk” aPL profile and con-
comitant risk factors and/or additional “APS non-criteria man-
ifestations,” therapeutic dose of heparin should be preferred
[80••].
Refractory Obstetric APS
However, current management does not prevent all maternal,
fetal, and neonatal complications of APS, and the current
treatment fails in 20 to 30% of APS pregnancies, raising the
need to explore other treatments to improve obstetrical out-
come. In these women with refractory ob-APS, treatment op-
tions to improve pregnancy outcomes include prednisolone
(10 mg/day, 0–14 weeks) and/or intravenous immunoglobulin
(IVIG) and/or plasmapheresis [86, 87•]. Great interest has
been given to drugs that could interact in the pathophysiolog-
ical mechanisms of the disease, such as hydroxychloroquine
(HCQ), statins, and certolizumab pegol (CTZ). As for HCQ, a
group of experts recommended HCQ in addition to conven-
tional treatment in those with APS and with previous preg-
nancy failure on current treatment [88]. Furthermore, an inter-
national task force highlighted the need for clinical trials of
HCQ in pregnant women with aPL and APS [89]. In vitro
studies suggested that HCQ inhibits aPL binding to tropho-
blasts restoring their function [90]; in a recent mouse model of
ob-APS, HCQ at a dose similar to the therapeutic dose in
human, prevented fetal death even the ex vivo gamma
counting, and immunohistochemical analysis did not affect
the aPL binding to the placenta [91•]. Three retrospective
studies have showed the benefits of HCQ in improving
APOs in APS patients in addition to conventional treatment
[92–94]. In a recentmulticenter retrospective study, highHCQ
(400 mg/day) versus low HCQ (200 mg/day) and its admin-
istration before versus during pregnancy was associated with a
significantly higher live birth rate in APS patients without
previous thrombosis [87•]. The HYPATIA study, a multicenter
randomized clinical trial (RCT), will start in the near future.
This will evaluate the efficacy of HCQ versus placebo in ad-
dition to standard of care in women with persistent aPL plan-
ning for pregnancy [95]. The HYDROSAPL, a French RCT,
will assess the efficacy of the addition of HCQ to conventional
treatment during pregnancy in ob-APS and thrombotic APS
[96] (Table 3).
Due to the similarities in pathophysiology among PE,
IUGR, and atherosclerotic cardiovascular disease, statins have
been proposed for treating and/or preventing these obstetrical
complications. Lefkou et al. reported on a small, observational
trial that showed a dramatic improvement in both maternal
and fetal/neonatal outcomes in women with APS given prav-
astatin (20 mg/day) in addition to LDA and heparin after the
onset of PE and/or IUGR comparedwith women in the control
group on conventional treatment [97•]. The protective effects
of pravastatin on the endothelium together with its effect in
restoring angiogenic balance might explain the amelioration of
placental and maternal preeclamptic signs. Keeping in mind the
potential role of TNF in the development of obstetric complica-
tions, an ongoing trial, the Improve Pregnancy in APS with
Certolizumab Therapy (IMPACT) study is evaluating if CTZ,
a TNF inhibitor that does not cross the placenta [98], reduces the
risk of APOs in high-risk APS patients [99] (Table 3).
Thrombotic and Obstetric APS
In ob-APS women with a history of a previous thrombotic
event, the treatment is based on secondary thromboprophylaxis
by using anti-thrombotic drugs and preventive strategies to
minimize the risk of recurrent thrombosis and reduce APOs
[100]. Since APS women with a previous thrombosis are usu-
ally treated with anticoagulation therapy, particularly with vita-
min K antagonist (VKA), it is important for these women to
discontinue VKA and switch to therapeutic LMWH and LDA
[101, 102], as soon as pregnancy is confirmed in order to avoid
fetal warfarin syndrome [103, 104], as a consequence of the
exposure to warfarin between the 6th and 12th gestational
week. In some countries (e.g., Brazil), the use of VKA is con-
sidered from the 13th week until the 36th week of gestation
[105], because of the impracticability of LMWH due to its cost.
Antithrombotic Management During the Delivery
Period
Another important aspect is the management of anti-
thrombotic and anti-platelet medications in these women dur-
ing delivery and the puerperium period. Even though the time
to stop treatment remains controversial, this depends mostly
on local protocols and the type of delivery programmed by the
obstetrician. Discontinuation of LDA depends on the centers
anesthesiologist experience and implemented hospital proto-
col. It is recommended that patients on anticoagulation with
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LMWH (at week 36–37) should switch to UFH and stop 4–6 h
prior to elective induction of delivery, cesarean section, or
neuraxial anesthesia [85]. However, if the patient is main-
tained on prophylactic/therapeutic LMWH, this should be
suspended 24 h prior to elective induction of delivery, cesar-
ean section, or neuraxial anesthesia.
Catastrophic APS
A special attention should be given to a rare and life-
threatening condition of APS called catastrophic
antiphospholipid syndrome (CAPS) that can develop in wom-
en during pregnancy [106]. The current management remains
challenging and consists as first-line therapy: (1)
anticoagulation, (2) pulse of corticosteroids, and/or (3) plas-
mapheresis, and/or (4) IVIG infusions [106]. In severe cases
of CAPS refractory to multiple treatments, current literature
reports successful cases using a second-line therapy with ri-
tuximab or eculizumab. The latter has been suggested in
several recent reports as a second-line treatment option in
APS and CAPS [106, 107], and recent data has shown that
only trace amounts of eculizumab passes the placenta [108•].
Associated Autoimmune Diseases in aPL/APS Women
The treatment of patients with ob-APS associated to other
autoimmune diseases should include HCQ in association to
LDA and prophylactic or therapeutic heparin depending on
the clinical (with or without previous thrombosis) and labora-
tory (low- vs high-risk) profile [80••]. It is still unknown the
risk of obstetric complications in aPL carriers, women positive
for aPL but without obstetric and thrombotic manifestations of
APS, or in women with obstetric morbidity not fulfilling
criteria for APS. Considering the pathogenic role of the aPL,
a stratification risk should be taken into account based on the
same risk factors mentioned above for definite ob-APS.
To date, few studies have been investigated the risk of
APOs in these women making it difficult to draw
Table 3 Human studies evaluating novel therapies in ob-APS
Drug Study,
year
Type of study Population (n) Main findings




APS [49] with 35 pregnancies LDA + LMWH vs HCQ + LDA + LMWH:
significant decrease of PrL from 81 to 19%








HCQ + LDA + LMWH: higher rate of live births
and a lower prevalence of overall pregnancy morbidity





(126 PDN0–14w + HCQ + LDA +
LMWH; 141 LDA + LMWH)
PDN + HCQ + LDA + LMWH: decrease in the incidence of
repeat PrL, miscarriage, and placental dysfunction-related
diseases and a significant increase in pregnancies lasting





Pregnant APS patients (194) HCQ 400mg vs 200mg, HCQ before vs during pregnancy:





aPL carriers and APS women who are
planning pregnancy (target sample
size: 328)
HCQ + LDA-LMWH vs placebo + LDA + LMWH.





ob-APS and t-APS during pregnancy
(target sample size: 220)
HCQ + LDA-LMWH vs placebo + LDA + LMWH.
Endpoint: rate of uncomplicated pregnancy
Pravastatin Lefkou E et al.,
2016
Retrospective ob-APS with PE and/or IUGR
(11 pravastin + LDA + LMWH vs 10
LDA + LMWH)
Pravastatin (20 mg/d) + LDA + LMWH: increased placental
blood flow and improvements in PE features
Eculizumab Gustavsen A et
al., 2017
Case report An APS pregnant woman with previous
arterial thrombosis and ongoing leg
ischemia
Two dose of eculizumab
(600 mg 8 and 1 day) before delivery: ischemic symptoms






High risk pregnant patients with APS or
SLE
(target sample size: 50)
CTZ + LDA + LMWH.
Endpoint:
1) rate of APOs in women with clinical APS and LAC, and
2) alterations in angiogenic markers of poor placental
vascularization
aPL antiphospholipid antibodies, APOs adverse pregnancy outcomes, APS anti-phospholipid syndrome, CTZ certolizumab pegol, HCQ
hydroxychloroquine, HYPATIA HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies, IMPACT IMProve
pregnancy in APS with Certolizumab Therapy, IUGR intrauterine grow restriction, LDA low-dose aspirin, LMWH low molecular heparin, PDN prednis-
olone, PE pre-eclampsia, PrL pregnancy losses, RCT randomized clinical trial, RSA recurrent secondary abortion, SLE systemic lupus erythematosus
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conclusions given the heterogeneity of type and number
of aPL tested [59•, 109–111]. LDA, also used in women
without aPL for the prevention of PE [112], has not been
shown to have efficacy as primary prophylaxis in reduc-
ing APOs in aPL carriers; but this systematic review in-
cluded only five studies involving 154 pregnancies [113].
However, in clinical practice, LDA is generally used to
manage aPL carriers during pregnancy, especially if one
or two fetal losses or maternal risk factors are present
[114]. In a large retrospective observational study, the rate
of pregnancy losses, gestational weight at delivery, and
birth weight percentile was not different between aPL
positive women treated with LDA and those not treated
[109]. The same data was confirmed in another large co-
hort of 73 pregnant aPL carriers (mostly isolated LA)
[110]. More recently, in a multicenter study, among 200
pregnant women positive for aPL, aPL carriers experi-
enced a similar number of APOs compared to ob-APS
(18%) and thrombotic APS (24%); triple aPL positivity
was associated to APOs even in aPL carriers on treatment
with LDA plus LMWH [60]. In another multicenter study
[111], APOs were observed in 9% of aPL carriers and
were associated to acquired traditional risk factors, “APS
non-criteria” or “lupus-like” manifestations and triple aPL
positivity. Interestingly, APOs occurred despite combina-
tion treatment with LDA and prophylactic LMWH, sug-
gesting that aPL carriers with multiple risk factors and a
“high-risk” aPL profile may require additional treatment,
such as therapeutic LMWH or HCQ. In the first-year
analysis of the European Registry on Obstetr ic
Antiphospholipid Syndrome (EUROAPS), women with
obstetric morbidity not fulfilling criteria for APS had
APOs similar to those with ob-APS and benefit from the
combination therapy with LDA and prophylactic LMWH
[78]. The beneficial role of HCQ in pregnant aPL carriers
has been hypothesized [115, 116], and the RCT
HYPATIA will assess the role HCQ in reducing APOs in
aPL carriers, too [95].
Perspectives
Promising results have been observed for novel pharma-
cological mechanisms that could prevent the binding of
either β2GPI or aβ2GPI to the trophoblast surface: the
binding site of domain V of β2GPI can be targeted by
the synthetic peptide TIFI [117]; a non-complement fixing
antibody to β2GPI domain 1 can prevent the binding be-
tween aPL and β2GPI [118]; the ob-APS phenotype can
be attenuated by the induction of tolerogenic dendritic
cells specific for β2GPI domain 1 [119]; and the binding
site of β2GPI to its receptors can be inhibited by the
1N11 monoclonal antibody [120].
Conclusions
Besides thrombotic microangiopathy, new pathogenic path-
ways involving uncontrolled inflammation support the devel-
opment of poor pregnancy outcomes. Further studies are re-
quired to deepen our understanding of how aPL cause ob-APS
and to clarify the epidemiology of ob-APS and its different
subsets. The current treatment regimen to prevent obstetric
morbidity in APS is based on LDA and heparin; this approach
has improved pregnancy outcomes to a live birth rate of over
70%. As nearly 30% of women continue to have pregnancy
complications, further studies are ongoing to assess different
options in order to improve pregnancy outcomes in women
with APS, especially in refractory ob-APS and aPL carriers.
HCQ seems to be a promising drug, based on experimental
and clinical studies. Other drugs interacting with the patho-
genic mechanisms of ob-APS such as eculizumab and statins
could be considered in selected complex cases.
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